ABOUT THE EDITORS

Adam Cuker, MD, MS, Executive Editor, is an Associate Professor of Medicine and of Pathology and Laboratory Medicine at the University of Pennsylvania. Dr. Cuker’s clinical and research interests include platelet disorders and other disorders of thrombosis and hemostasis.

Ann S. LaCasce, MD, MMSc, Deputy Editor, is an Associate Professor of Medicine at the Dana-Farber Cancer Institute, where she is a member of the lymphoma program and serves as the Program Director for the Dana-Farber Partners Cancer Care Fellowship in Hematology/Oncology. Her research focuses on development of novel drugs and approaches in Hodgkin and non-Hodgkin lymphoma.

Mario Cazzola, MD, Deputy Editor, is a former Professor of Hematology at the University of Pavia and is currently a group leader in research projects on myeloid neoplasms at Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. He has a special interest in the genetic basis of myelodysplastic syndromes and myeloproliferative neoplasms, with an ultimate aim to develop precision medicine approaches to diagnosis, prognostication, and treatment of these disorders.

Stella T. Chou, MD, Deputy Editor, is an Associate Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania and practices pediatric hematology and transfusion medicine at the Children’s Hospital of Philadelphia. Dr. Chou’s clinical and research interests include development of innovative molecular and cellular tools to personalize transfusion therapy for patients with sickle cell disease. Her research laboratory uses induced pluripotent stem cells to create in vitro-derived red cells and to model pediatric blood diseases to study their underlying pathophysiology.

David A. Garcia, MD, Special Section Editor, is Assistant Medical Director for Antithrombotic Therapy at the University of Washington Medical Center and Professor of Medicine in the Division of Hematology at the University of Washington. His clinical practice and research are focused on the prevention and treatment of venous thromboembolism.

The American Society of Hematology
2021 L Street, NW
Suite 900
Washington, DC 20036

Hematology 2021: the American Society of Hematology Education Program is supported by educational grants from AstraZeneca; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals; Pfizer Inc.; and Vertex Pharmaceuticals Inc.